Opko Health Inc Stock News

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (NASDAQ: ADGI) announced th

OPKO Health (NASDAQ:OPK) is scheduled to announce Q4 earnings results on Thursday, Feb. 24, after market close.Consensus EPS estimate is -$0.02 (vs. $0.05 in year-ago period)

WASHINGTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research''s recent analysis of the Global Prostate Specific Antigen (PSA) Testing Market finds that rising prostate cancer among men, who are over 50 years in age is augmenting the growth of Prostate Specific Antigen (PSA) Testing Market in the coming years. In addition, various inventions for the diagnosis of prostate cancer and development of various assay-based methods have increased the demand for PSA testing. This improved technology is used to provide accuracy and specificity of the results, thus, helps in improving the Prostate Specific Antigen (PSA) Testing Market demand. The total Global Prostate Specific Antigen (PSA) Testing Market is estimated to reach USD 5.83 Billion by 2028. The market stood at a revenue of USD 3.12 Billion in 2021, and is expected to grow at a Compound Annual Growth Rate (CAGR) of 11.2%, states Vantage Market Research, in a report, titled " Prostate Specific Antigen (PSA) Testing Market by Test Type (Preliminary Tests, Confirmatory Tests), by Region (North America, Europe, Asia Pacific, Latin America) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)".

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front, the Food and Drug A

In the latest trading session, OPKO Health (OPK) closed at $3.15, marking a +0.32% move from the previous day.

In the latest trading session, OPKO Health (OPK) closed at $3.15, marking a +0.32% move from the previous day.

With equity prices soaring to record levels, many execs have cashed out. Here are the insider stocks where execs are cashing in.

MIAMI, Feb. 17, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months…

MIAMI, Feb. 17, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended December 31, 2021 after the close of the U.S. financ

Pfizer (PFE) gets approval for pediatric growth hormone deficiency drug, Ngenla (somatrogon) and 20-valent pneumococcal conjugate vaccine, Apexxnar, in Europe.

OPKO's (OPK) marketing authorization for NGENLA in the European Union stands to benefit children and adolescents affected by growth hormone deficiency.

Although US stock futures traded slightly lower this morning, there were a few notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the compan

The European Commission has approved Ngenla (somatragon), a long-acting recombinant human growth hormone to treat pediatric growth hormone deficiency, from Pfizer (PFE) and OPKO (OPK).

OPKO Health's (OPK) fourth-quarter results are likely to reflect strength in Rayaldee.

NEW YORK & MIAMI--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. (NASDAQ: OPK) announced today that the European Commission has granted marketing authorization for the next-generation long-acting recombinant human growth hormone NGENLA™ (somatrogon), a once-weekly injection to treat children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone. NGENLA provides pediatric patients, their caregivers and healthcare providers wit